Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 9, 2026, discloses a material definitive agreement entered into by Jaguar Health, Inc. (the "Company") and its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"). The filing addresses the renewal of the manufacturing and supply relationship for crofelemer, the active ingredient in the Company's FDA-approved product, Mytesi®.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on the terms of a contractual agreement rather than financial performance results.
Material Changes and Agreement Terms
On July 9, 2026, Napo and Alivus Life Sciences Limited ("Alivus") executed a new Manufacturing and Supply Agreement (the "2026 Agreement"), replacing the prior agreement that expired on March 31, 2026. Key terms include:
- Term: The agreement expires on March 31, 2029, with options for successive two-year renewal terms by mutual agreement.
- Supply Commitment: Napo is committed to purchasing minimum quantities of crofelemer from Alivus, pro-rated for the financial year. The Company may be obligated to pay for any shortfall in these minimum quantities.
- Capacity Limits: Required quantities shall not exceed amounts set forth per calendar quarter unless capacity expansion is requested in writing by Napo.
- Termination Rights:
- Either party may terminate for any reason with 12 months' prior written notice.
- Termination is permitted for material breach uncured for 90 days.
- Immediate termination is allowed for bankruptcy, insolvency, or inability to pay debts.
- Napo may terminate immediately if regulatory authorities withdraw the product for safety reasons or upon 30 days' notice for chronic failure to supply.
- Insolvency Contingency: If an "Insolvency Event" occurs, Napo's rights and obligations under this agreement will be assigned to Woodward Specialty LLC (an affiliate of Future Pak, LLC) pursuant to a separate License Agreement dated January 12, 2026.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary regarding future earnings. However, it highlights specific operational risks:
- Supply Chain Dependency: The Company relies on Alivus as the manufacturer for crofelemer. Chronic failure to supply could trigger termination rights.
- Regulatory Risk: Immediate termination is possible if the FDA or other authorities withdraw the product due to safety or non-compliance issues.
- Financial Obligation: The Company faces potential liability for paying shortfalls against minimum purchase commitments if demand does not meet the agreed thresholds.
Investor Verification Checklist
- Verify the specific minimum quantity commitments and associated financial penalties for shortfalls in the full text of Exhibit 10.1 (redacted portions may obscure exact figures).
- Confirm the status of the January 12, 2026, License Agreement with Woodward Specialty LLC and Future Pak to understand the full scope of the insolvency contingency plan.
- Review recent quarterly reports (10-Q) or annual reports (10-K) for the most current revenue, cash flow, and liquidity data, as this 8-K does not contain them.
- Monitor regulatory communications regarding Mytesi® to assess the risk of product withdrawal.